|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18 Pt 1
|
|
pubmed:dateCreated |
2007-9-18
|
|
pubmed:abstractText |
MS-275 is a histone deacetylase inhibitor that has shown potent and unique anticancer activity in preclinical models. The aims of this phase I trial were to determine the dose-limiting toxicities and maximum tolerated dose of oral MS-275 in humans administered with food on a once weekly schedule and to study the pharmacokinetics of oral MS-275.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:ChenAliceA,
pubmed-author:ChungEun JooEJ,
pubmed-author:ConleyBarbaraB,
pubmed-author:DonovanErinE,
pubmed-author:DoroshowJames HJH,
pubmed-author:FiggWilliam DWD,
pubmed-author:GardnerErin RER,
pubmed-author:GutierrezMartinM,
pubmed-author:HwangKyunghwaK,
pubmed-author:KalnitskiyMikhailM,
pubmed-author:KummarShivaaniS,
pubmed-author:LeeMin-JungMJ,
pubmed-author:MaynardKimK,
pubmed-author:MelilloGiovanniG,
pubmed-author:MurgoAnthony JAJ,
pubmed-author:RyanQin CQC,
pubmed-author:TrepelJane BJB,
pubmed-author:ZwiebelJamesJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5411-7
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17875771-Adult,
pubmed-meshheading:17875771-Aged,
pubmed-meshheading:17875771-Antineoplastic Agents,
pubmed-meshheading:17875771-Benzamides,
pubmed-meshheading:17875771-Drug Administration Schedule,
pubmed-meshheading:17875771-Enzyme Inhibitors,
pubmed-meshheading:17875771-Female,
pubmed-meshheading:17875771-Histone Deacetylase Inhibitors,
pubmed-meshheading:17875771-Humans,
pubmed-meshheading:17875771-Lymphoma, Non-Hodgkin,
pubmed-meshheading:17875771-Male,
pubmed-meshheading:17875771-Maximum Tolerated Dose,
pubmed-meshheading:17875771-Middle Aged,
pubmed-meshheading:17875771-Neoplasms,
pubmed-meshheading:17875771-Pyridines
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
|
|
pubmed:affiliation |
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA. kummars@exchange.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural,
Research Support, N.I.H., Intramural
|
